RE: Nice17 Jul 2020 12:10
ClearStar (AIM: CLSU), a provider of Human Capital Integrity? technology-based services specialising in background and medical screening, announces the launch of a testing service aimed at supporting employers with their COVID-19 return-to-work planning and keeping their workforce safe. The new service is provided by ClearStar's Medical Information Services ("MIS") business through Clinical Reference Laboratory, Inc. ("CRL"), one of the largest privately held clinical testing laboratories in the US, and it includes both an antibody and a diagnostic test.
In the first instance, employees receive the CRL Clear™ kit, which is a dried blood spot finger prick test that is used to identify the presence, or lack, of COVID-19 antibodies in the blood, which are produced by the body in response to the virus. This includes IgA, IgM and IgG antibodies, which are produced at different stages of the immune system response.
A positive test result indicates that the employee has been previously infected by COVID-19 and has developed antibodies that might provide the employee with immunity. The CRL Clear™ kit is based on the Roche Elecsys® Anti-SARS-CoV-2 antibody test, which has received the CE mark and US Food and Drug Administration Emergency Use Authorization.
https://www.investegate.co.uk/clearstar-inc---clsu-/rns/launch-of-covid-19-testing-service-for-employers/202005210700095524N/